Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease

The incidence of neurodegenerative diseases, such as Alzheimer’s disease (AD), is continuously growing worldwide, which leads to a heavy economic and societal burden. The lack of a safe and effective causal therapy in cognitive decline is an aggravating factor and requires investigations into the re...

Full description

Bibliographic Details
Main Authors: Gabriela Dumitrita Stanciu, Daniela Carmen Ababei, Carmen Solcan, Veronica Bild, Andrei Ciobica, Sorin-Ioan Beschea Chiriac, Loredana Maria Ciobanu, Bogdan-Ionel Tamba
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Pharmaceuticals
Subjects:
Alzheimer’s disease
SGLT2i
canagliflozin
donepezil
acetylcholinesterase inhibitor
mTOR
Online Access:https://www.mdpi.com/1424-8247/16/11/1620

Internet

https://www.mdpi.com/1424-8247/16/11/1620

Similar Items